Researchers Discover Llama-Derived Nanobody Can Be Used as Potential Therapy for Hard-to-Treat Diseases
Finding holds promise to advance targeted treatment for neurological diseases and cancer
Researchers from Case Western Reserve University School of Medicine have found a nanobody that holds promise to advance targeted therapies for a number of neurological diseases and cancer.
Sahil Gulati, of the Department of Pharmacology at Case Western Reserve School of Medicine, and colleagues identified a nanobody derived from a llama that targets signaling of G protein-coupled receptors (GPCRs), a large family of receptors involved with transmitting signals in cells.
The llama-derived nanobody specifically targets a component of G protein known as G beta-gamma–the part that binds and efficiently activates several other signaling proteins. These proteins, once activated, have been linked to several types of cancers, neurological disorders and drug addiction.
Click here to read more.
The New England Master Class - Anterior Skull Base Surgery
May 20-21, 2019; Boston
6th Annual Meeting on Neurosurgery and Neurologica
May 22-23, 2019; London
INS 14th World Congress
May 25-30, 2019; Sydney
12th Annual Cervical Spine Research Society Hands-on Cadaver Course
May 30-June 1, 2019; St. Louis
Brain Tumor Biotech Summit
June 7, 2019; New York